Figure 1 (Zontivity 01)
Zontivity
Product Images NDC 66992-208
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zontivity (NDC 66992-208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Wraser Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Zontivity 02)
Figure 2 (Zontivity 03)
This appears to be a table containing information regarding the impact of intrinsic factors on Moan Effoct and 90% €1 Dose Adjustment. The factors mentioned include Age, Gender, Race, Renal impairment, and Hepatic impairment. The table provides recommendations on whether or not dose adjustment is needed based on the factors present. The last row suggests the recommended use of the tool or information. There appears to be a reference to a "Ghanga Ratio to Refrenca" but without further context, it is unclear what this means.*
Figure 3 (Zontivity 04)
This is a description of different types of medication. It includes antacids, specifically Gaviscon Extra Strength in liquid form, a proton pump inhibitor called Pantoprazole at 0mg, and Prasugrel at 10mg. Additionally, there is mention of a "Moan Effectand 30% C1 Dose Adjustment" and advice to avoid certain combinations of medication. The numbers listed at the bottom do not provide clear context.*
Figure 4 (Zontivity 05)
This text provides information on dose adjustment requirements for drugs interacting with certain enzymes and substrates. Specifically, the chart shows the mean effect and 90% confidence interval for interacting drugs, with dosage adjustments required for P-gp substrate Digoxin and the warning to avoid concurrent use of CYP2C9 substrate Warfarin with other drugs. Additionally, information on the dosage requirements for Prasugrel, R(+) enantiomer, and S(+) enantiomer for CYP2C8 substrate Rosigitazone are provided. Overall, this document serves as a tool for adjusting medication doses for their interactions with specific enzymes and substrates.*
Figure 5 (Zontivity 06)
The text describes the incidence rates, placebo and ZONTIVITY groups, and the results of a clinical trial. Not available information about the purpose and nature of the clinical trial.*
Figure 6 (Zontivity 07)
Principal Display Panel (30 Tablet Bottle Label)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
